Search This Blog

WHAT'S NEW IN TUBERCULOSIS

Tuesday 20 April 2010

P-MAPA

The main focus of the work of Farmabrasilis has been the development of the immunomodulator P-MAPA. Although this compound was originally intended for cancer treatment and has been shown to have anti-tumour activity, P-MAPA also modulates the production of interferon-gamma and interleukin-10, known to be key substances in the body’s defences against TB, malaria and other infectious diseases. This had led Farmabrasilis to put forward a new approach to treating patients with these conditions - including those co-infected with HIV - which would involve attempting to re-establish patients’ immunocompetence by adjuvant immunotherapy with P-MAPA.
Farmabrasilis welcomes contact with other individuals and organizations interested in the further development of the proposed approach.
Tests carried out by Tuberculosis Antimicrobial Acquisition and Coordinating Facility (TAACF) under contract signed by Farmabrasilis and US NIAID has shown that P-MAPA is active against M. tuberculosis in vivo

http://blog.tropika.net/tropika/2010/04/19/news-from-farmabrasilis/

No comments: